Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction

医学 帕利骨化醇 彭布罗利珠单抗 内科学 胰腺癌 肿瘤科 骨化三醇受体 肿瘤微环境 继发性甲状旁腺功能亢进 癌症 维生素D与神经学 免疫疗法 钙 甲状旁腺激素
作者
Vincent Chung,Angela Alistar,Carlos Becerra,Anup Kasi,Erkut Borazanci,Gayle Jameson,Denise J. Roe,Betsy C. Wertheim,Derek Cridebring,Morgan Truitt,Michael Downes,Michael T. Barrett,Ron Korn,Keehoon Lee,Haiyong Han,Ronald M. Evans,Daniel D. Von Hoff
出处
期刊:Oncologist [AlphaMed Press]
卷期号:30 (1) 被引量:7
标识
DOI:10.1093/oncolo/oyae323
摘要

Abstract Lessons learned Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life. Background Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor microenvironment playing a key role in immune resistance. In preclinical studies, vitamin D receptor (VDR) agonists have been shown to sensitize pancreatic tumors to PD-1 blockade. Methods This was a randomized, double-blinded, placebo-controlled, phase II trial to evaluate pembrolizumab with or without paricalcitol as maintenance therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants were ≥18 years; histologically or cytologically confirmed metastatic PDAC showing no disease progression after frontline systemic therapy, and achieving maximal cytoreduction (eg, with no further antitumor effect), Eastern Cooperative Oncology Group (ECOG) status of 0 or 1; adequate organ function. Study treatment included: pembrolizumab 200 mg IV every 3 weeks and either paricalcitol 25 mcg IV 3 times per week or placebo. The primary objective was to evaluate 6-month progression free survival (PFS). Secondary objectives include evaluating the toxicity of the combination and overall survival (OS). Results There was no significant difference in 6-month PFS, median PFS, median OS, nor treatment-related AEs between the 2 arms. Conclusions and relevance Paricalcitol did not improve the efficacy of pembrolizumab likely related to its short half-life of only 5-7 hours. Microbiome analysis revealed significant difference between long-term (>12 weeks) and short-term (<12 weeks) survival groups across treatment arms. Modulation of the tumor microenvironment will likely require more sustained VDR activity. Trial Registration Clinicaltrials.gov, ID: NCT03331562.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
2秒前
2秒前
科目三的应助被欧耶采纳,获得10
2秒前
VV发布了新的文献求助10
3秒前
4秒前
李爱国的应助被阿东采纳,获得10
4秒前
Yrzyc发布了新的文献求助10
4秒前
灯笔忆扬完成签到 ,获得积分10
4秒前
badjack发布了新的文献求助10
5秒前
SGOM完成签到 ,获得积分10
5秒前
5秒前
Wa1Zh0u完成签到,获得积分10
5秒前
5秒前
7秒前
lele发布了新的文献求助30
7秒前
水煮电吹风的应助被rio采纳,获得10
7秒前
8秒前
8秒前
今后的应助被三分之二采纳,获得10
8秒前
9秒前
西贡老王发布了新的文献求助10
9秒前
无花果的应助被洁净的千凡采纳,获得10
9秒前
小马甲的应助被lnfuture采纳,获得20
10秒前
bobo完成签到,获得积分10
11秒前
Hello的应助被开心采纳,获得10
12秒前
Orange的应助被苹果丑采纳,获得30
13秒前
灝男发布了新的文献求助30
13秒前
阮大帅气完成签到,获得积分10
14秒前
14秒前
打老虎发布了新的文献求助10
14秒前
saflgf发布了新的文献求助10
14秒前
15秒前
xm完成签到,获得积分10
17秒前
涵霸天发布了新的文献求助10
18秒前
liuyi发布了新的文献求助10
18秒前
18秒前
gao完成签到,获得积分10
18秒前
脑洞疼的应助被succo采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055